Compare PSEC & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSEC | AMPH |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2004 | 2014 |
| Metric | PSEC | AMPH |
|---|---|---|
| Price | $2.63 | $29.33 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 3.9M | 332.7K |
| Earning Date | 02-09-2026 | 02-26-2026 |
| Dividend Yield | ★ 20.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.27 |
| Revenue | $680,752,000.00 | ★ $723,305,000.00 |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $4.84 |
| P/E Ratio | ★ N/A | $12.89 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.45 | $20.39 |
| 52 Week High | $4.47 | $33.42 |
| Indicator | PSEC | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 66.12 |
| Support Level | $2.68 | $28.45 |
| Resistance Level | $2.77 | $29.37 |
| Average True Range (ATR) | 0.08 | 0.86 |
| MACD | -0.03 | 0.28 |
| Stochastic Oscillator | 2.84 | 93.33 |
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.